Clinical trials: PCA
Pain, Postoperative
A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous Pump
The purpose of this study is to compare two pain medications delivered by two different forms of patient-controlled pain management systems: the Fentanyl HCl Patient-Controlled Transdermal System (E-TRANS fentanyl) and the…
- Trial name
- NCT00266539
- Testing
- E-TRANS Fentanyl hydrochloride; Morphine
- Volunteers
- 506 people
- Sponsor
- Alza Corporation, DE, USA
Prostate Cancer
Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
The purpose of this study is to evaluate the effect of an initial hormonal treatment gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in patients with histologically confirmed and advanced…
- Trial name
- Triptocare (NCT01020448)
- Testing
- Triptorelin (Decapeptyl®)
- Where
- 59 sites in Belgium, Denmark and 8 more
- Volunteers
- 339 people
- Sponsor
- Ipsen
Stroke, Acute, Middle Cerebral Artery Stroke
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke
The primary objective of the study is to assess the safety and tolerability of Human Placenta-Derived Cells (PDA001) at 3 different dose levels versus placebo (vehicle control) administered intravenously in subjects following…
- Conditions
- Stroke, Acute, Middle Cerebral Artery Stroke, Posterior Cerebral Artery Stroke
- Trial name
- NCT01310114
- Testing
- Human Placenta-Derived Cells PDA001- (cenplacel-L)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Celularity Incorporated
Prostate, Cancer
Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based…
- Trial name
- VOYAGER (NCT06192758)
- Testing
- TheraSphere PCa
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Prostate Cancer
Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer
The purpose of this study is to assess the safety of the second cycle of DCVAC/PCa in patients who completed the first cycle of DCVAC/PCa in the clinical trial SP003 without an objective progression of the disease.
- Trial name
- NCT02137746
- Testing
- Dendritic Cells DCVAC/PCa
- Where
- 7 sites in Czechia
- Volunteers
- 24 people
- Sponsor
- SOTIO a.s.
Healthy
Components of Chlorhexidine Gluconate Dressing
The purpose of this study is to determine the contents of a chlorhexidine-containing dressing after use.
- Trial name
- NCT01112020
- Testing
- CHG Catheter Dressing Patch, Biopatch, Tegaderm CHG
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- C. R. Bard
Castration-resistant Prostate Cancer
A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer
This clinical trial is to evaluate the safety of the combination of DCVAC/PCa with ONCOS-102 in men with castration-resistant advanced metastatic prostate cancer, who have progressed following initial therapy with either hormones…
- Trial name
- NCT03514836
- Testing
- DCVac/PCa, Cyclophosphamide
- Where
- Czechia
- Volunteers
- 5 people
- Sponsor
- SOTIO a.s.
Postoperative Pain
Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty
This is a Phase 2 3-arm, open label pilot study of the safety and efficacy of Q8003 in patients who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty.
- Trial name
- NCT00818493
- Testing
- Q8003 (morphine sulfate and oxycodone hydrochloride), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride), Percocet (oxycodone and acetaminophen)
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- QRxPharma Inc.
Metastatic Castration-resistant Prostate Cancer
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
The VIABLE study sought to confirm the hypothesis that the combination of docetaxel with DCVAC/PCa followed by a maintenance therapy with DCVAC/PCa would improve overall survival in patients with metastatic castration-resistant…
- Trial name
- VIABLE (NCT02111577)
- Testing
- DCVAC/PCa
- Where
- 177 sites in United States, Austria and 20 more
- Volunteers
- 1,182 people
- Sponsor
- SOTIO a.s.
Pain, Postoperative
Evaluation of Oral PCA Device - PCoA™ Acute
Randomized, open label, controlled pilot clinical study comprised hospitalized post operative patients receiving oral analgesics.
- Trial name
- NCT03134001
- Testing
- patients receiving oral analgesics via the PCoA™ Acute
- Volunteers
- 70 people
- Sponsor
- Dosentrx Ltd.
Alzheimer Disease, Parkinson Disease
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
- Trial name
- MemorEM (NCT07222605)
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- eQ8Health Corporation d/b/a CareONE Concierge
Post-Operative Pain
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery
The purpose of this study is to compare the efficacy and safety of the Sufentanil NanoTab PCA System/15 mcg to the Placebo Sufentanil NanoTab PCA System for the management of acute moderate to severe post-operative pain after…
- Trial name
- NCT01539642
- Testing
- Sufentanil NanoTab PCA System/15 mcg
- Where
- 12 sites in United States
- Volunteers
- 172 people
- Sponsor
- Talphera, Inc
Prostate Cancer, Prostate Cancer Metastatic
Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care therapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer
- Trial name
- NCT02105675
- Testing
- Dendritic Cells DCVAC/PCa, Docetaxel
- Where
- 10 sites in Czechia
- Volunteers
- 60 people
- Sponsor
- SOTIO a.s.
Neoplasms, Prostate, Prostate Cancer
Korean Practice Patterns for Screening PCA(Prostate Cancer)
This is to investigate Korean urologist's practice patterns for screening prostate cancer according to PSA level.
- Conditions
- Neoplasms, Prostate, Prostate Cancer, Benign Prostatic Hyperplasia
- Trial name
- RESPECT (NCT01371513)
- Testing
- continuous screening
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Plasma Concentrations
Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab
Determine the plasma concentration profile after single and multiple dosing of Sufentanil NanoTabs
- Trial name
- NCT01761565
- Testing
- Single dose of SUF NT 15 mcg, 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Talphera, Inc
Prostate Cancer
Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added after radical primary prostatectomy can improve PSA progression times within 5 years for patients with high risk localized Prostate Cancer.
- Trial name
- NCT02107430
- Testing
- Dendritic Cells DCVAC/PCa, Standard radiotherapy
- Where
- 6 sites in Czechia
- Volunteers
- 62 people
- Sponsor
- SOTIO a.s.
Prostate Cancer
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia
The objective of this study was to describe treatment patterns of leuprorelin over 2 years using an intermittent, adjuvant regimen in participants with advanced prostate cancer (PCa)
- Trial name
- NCT01320735
- Volunteers
- 300 people
- Sponsor
- AbbVie (prior sponsor, Abbott)